Makis Pharma

Makiz-Pharma (commonly referred to as Makis Pharma) is a leading Russian pharmaceutical manufacturer headquartered in Moscow. Established in 2000, the company focuses on the production of finished dosage forms across several therapeutic segments, including cardiovascular, infectious diseases (HIV, hepatitis, tuberculosis), and oncology. In 2014, Makiz-Pharma was acquired by the Indian pharmaceutical company Hetero, becoming its primary manufacturing hub in Russia. The facility operates according to international GMP standards and plays a vital role in the Russian government's import substitution strategy by producing essential generic medications locally. The company is currently expanding its capabilities to include a full production cycle, from active pharmaceutical ingredient synthesis to final product packaging.